Advances In The Treatment Of Non Small-cell Lung Cancer With Endostar

Tumor growth depends on blood vessels.Recombinant human endostatin(Endostar),as first class of national cancer drugs,can specifically inhibit tumor angiogenesis,thus inhibiting the tumor proliferation。At present,clinical researchs of Endostar have not been reported abroad yet.Based on good results of phrase III trail of Endostar,led by Cancer Hospital,Chinese Academy of Medical Sciences,Endostar has been approved by SFDA to be used in the first line treatment of patients with advanced non-small cell lung cancer(NSCLC).In recent years,more and more researches about its application in the second line treatment of patients with advanced NSCLC,in the treatment of patients with localy advanced NSCLC and in the treatment of postoperative complementary therapy on patients with NSCLC are on the increase.In addition,the researches of the dosage of administration,methods of medication and routes of administration are carried out gradually,which may facilitate its application in clinical.The clinical advances of the application of Endostar in the treatment of patients with NSCLC and its best use patterns will be reviewed.